Overview
HENLIUS (2696)
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic disea...
- Open
- 48.300
- High
- 49.460
- Low
- 43.020
- Prev. Close
- 48.120
- Volume
- 1.84M
- Turnover
- 81.96M
- Avg Price
- 44.520
- Bid/Ask Ratio
- 83.84%
- Amplitude
- 13.38%
- 52wk High
- 87.100
- Volume Ratio
- 2.95
- Turnover Ratio
- 0.53%
- 52wk Low
- 43.020
- HK Mkt Cap
- 15.60B
- Market CapHKD
- 24.45B
- P/ETTM
- 24.48
- P/EDynamic
- 24.67
- P/EStatic
- --
- EPSTTM
- 1.83
- EPSDynamic
- 1.82
- EPSStatic
- --
- BVPS
- 9.58
- P/B
- 4.68
- HK Shares
- 347.88M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 545.30M
- Min lot size
- 100
- Currency
- HKD
HENLIUS Analyst Rating
View moreForecast & Rating
Nov 12, 2026- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 8
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Henlius dropped 6.3% to HK$45.08 from HK$48.12, with an early high near HK$48.20 giving way to a 10:53 BJ low of HK$43.14, just above the 52-week low of HK$43.02, as the recent board reshuffle overshadowed the addition of HANSIZHUANG and FUTUONING to the 2026 NRDL. The session recorded HK$80.3 million of turnover on 1.80 million shares. The intraday range of HK$5.06, about 10.5% from high to low, underscores the scale of the reversal. Fundamentals remain solid: Q2 revenue rose 34.15% year on year to HK$2.07 billion, net profit gained 16.3% to HK$248.6 million, EPS reached HK$0.4562 for a 16.01% increase, and ROE stood at 18.97%. Even so, the stock trades below its MA20 of HK$49.67 and MA60 of HK$57.29, is down 23.07% year to date, sits 48.24% below the 52-week high of HK$87.10, and carries a 24.62x PE and 4.70x PB. Positive ASTRIDE U.S. bridging data for serplulimab plus chemotherapy in ES-SCLC did not arrest the decline, though the NRDL inclusion still contrasts with the price action. The 52-week low was set only a day earlier, on 2026-11-15.
- Nov, 13
Henlius fell 3.12% to HK$48.42 after an early probe to HK$50.00 faded, sliding to HK$47.46 at 13:25 BJ before closing near the afternoon open on HK$22.46 million turnover. Guotai Haitong reiterated a Buy rating, positive ASTRIDE US bridging-study results for serplulimab plus chemotherapy in first-line ES-SCLC and Australian Phase 1 clearance for HLX109 were set against the board's proposal to lift the 2026 HLX01 collaboration cap to RMB714 million. Price sits below the MA20 of HK$50.00 and MA60 of HK$57.72, down 17.37% YTD and 44.41% from the 52-week high of HK$87.10, though still 6.42% above the 2 November low of HK$45.50. Q2 revenue of HK$2.07 billion grew 34.15% yoy with net profit up 16.3% to HK$249 million and ROE at 18.97%, against PE of 26.44x and PB of 5.05x, so today's pullback ran against that backdrop; licensing and trial milestones remain the swing factor.
- Nov, 9
Hong Kong biopharma names rallied across the board and Henlius staged a spike-and-fade: the stock touched HK$52.00 at 09:35 BJ, roughly 6% above the HK$49.02 prior close, then bled lower through the afternoon session to HK$49.68 and last printed near HK$49.78. The morning pop traced to Australian TGA clearance for a Phase 1 trial of HLX109, an IL1RAP-targeting antibody for generalized pustular psoriasis, layered on positive ASTRIDE US bridging results for serplulimab plus chemotherapy in first-line ES-SCLC. Fundamentals still outrun the tape, with Q2 2026 revenue up 34.15% yoy, net profit up 16.3% yoy and ROE at 18.97%, yet the price sits below both the MA20 of HK$50.47 and the MA60 of HK$58.90, down 15.05% year-to-date and 42.85% beneath the HK$87.10 52-week high. Though at 27.18x PE and 5.19x PB, further re-rating still hinges on pipeline delivery.
- Nov, 4
Henlius staged a dip-then-rebound session, closing at HK$48.14 for a 3.70% gain after opening at HK$47.24, sliding to HK$46.50 in the morning and then pushing up to HK$49.98 in the afternoon on 1.493 million shares worth about HK$72.9 million. The driver was the positive ASTRIDE U.S. bridging study of serplulimab (H drug) with chemotherapy in first-line extensive-stage small cell lung cancer, selected for an ESMO oral presentation, alongside GIC adding 592,000 shares at HK$52.5738 and CEO Zhu Jun buying 20,000 shares at HK$49.92. Q2 2026 revenue reached HK$2.072 billion, up 34.15% year on year, with net profit of HK$248.6 million up 16.3%. Yet the shares remain below the MA20 of HK$50.91 and the MA60 of HK$59.87, down 17.85% year to date and 44.73% below the April 7 52-week high of HK$87.10, only 5.8% above the November 2 low of HK$45.50, while profit growth of 16.3% trails revenue growth.
- Oct, 22
2696.HK reversed an early gain and closed at HK$49.42, down about 8%, after touching HK$53.85 in the morning session when the ESMO congress selected the US bridging ASTRIDE study of its H drug for an oral presentation, then sliding to an intraday low of HK$48.86 in the afternoon. Fundamentals contrast with the tape: Q2 2026 revenue reached HK$2.07bn, up 34.15% yoy, with net profit of HK$248.6m up 16.3%, EPS of HK$0.4562 up 16.01% and ROE near 18.97%. The stock sits 15.67% lower year-to-date, 43.26% below its 52-week high of HK$87.10 and just 3.78% above the 52-week low of HK$47.62, while trading below both its MA20 of HK$54.74 and MA60 of HK$61.52. CITIC Securities maintained its Buy rating with a HK$122 target, and CEO Zhu Jun added 20,000 shares at HK$49.92 each. Volume was light at 838,300 shares, a 0.24% turnover rate, with PE at 26.99x.
News
PUBT · Shanghai Henlius Wins China Approval for Phase 1 Trial of HLX105 Cancer Treatment
Market Movers · Henlius drops nearly 6% to hit 52-week low
Tip Ranks · Henlius Announces HANSIZHUANG and FUTUONING Additions to 2026 NRDL
Tip Ranks · Shanghai Henlius Biotech, Inc. Class H (2696) Receives a Buy from Guotai Haitong
Simplywall · Could Serplulimab Trial Results Alter The Investment Case For Henlius Stock?
Market Movers · Henlius climbs 6%
